Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95 Carcinoma, Non-Small-Cell Lung 87 Lung Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 19 Melanoma 19 Triple Negative Breast Neoplasms 14 Stomach Neoplasms 13 Breast Neoplasms 13 Neoplasm Metastasis 11 Head and Neck Neoplasms 11 Carcinoma, Renal Cell 11 Endometrial Neoplasms 10 Urinary Bladder Neoplasms 9 Neoplasms 9 Carcinoma 9 Carcinoma, Transitional Cell 7 Carcinoma, Hepatocellular 7 Colorectal Neoplasms 6 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neoplasms by Site 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Thoracic Neoplasms 3 Small Cell Lung Carcinoma 3 Skin Neoplasms 3 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Lung Diseases 3

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × pembrolizumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡